NCT05035979

Brief Summary

We designed the study as a double-blind,randomized,controlled clinical trial.The aim of this trial is to clarify the treatment efficacy, safety, and recurrence control of BaiDi QuZhi(BDQZ) granule combined with Ju Yin(JY) cream in the treatment of acne vulgaris.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
472

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Dec 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 13, 2020

Completed
1.2 years until next milestone

First Posted

Study publicly available on registry

September 5, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

December 1, 2021

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

September 5, 2021

Status Verified

August 1, 2021

Enrollment Period

1.6 years

First QC Date

June 13, 2020

Last Update Submit

September 3, 2021

Conditions

Keywords

Acne VulgarisRandomized controlled trialBaiDI QuZhi granuleJu YIn creamTraditional Chinese Medicine

Outcome Measures

Primary Outcomes (1)

  • Success rate of the investigators' overall assessment (IGA) for acne vulgaris

    On the IGA (0-5) score, the percentage of subjects with IGA score reduction (baseline IGA- week 8 IGA) greater than or equal to 2 points.

    up to 16th weeks

Secondary Outcomes (8)

  • skin lesion count (total, inflammatory and non-inflammatory)

    Patients will be evaluated at the 2st, 4nd, 6rd, 8th week and follow-up period (12th, 16th week).

  • Visual analogue scale (VAS) score of facial itching symptoms

    Patients will be evaluated at the 2st, 4nd, 6rd, 8th week and follow-up period (12th, 16th week).

  • Visual analogue scale(VAS) score of facial pain symptoms

    Patients will be evaluated at the 2st, 4nd, 6rd, 8th week and follow-up period (12th, 16th week).

  • Skindex-16 scale

    Patients will be evaluated at the 2st, 4nd, 6rd, 8th week and follow-up period (12th, 16th week).

  • Traditional Chinese Medicine(TCM) syndrome score

    Patients will be evaluated at the 2st, 4nd, 6rd, 8th week and follow-up period (12th, 16th week).

  • +3 more secondary outcomes

Study Arms (4)

TCM comprehensive treatment group

EXPERIMENTAL

Participants in the TCM treatment group will receive BaiDi Quzhi granule two times daily after meals, Ju Yin cream therapy three times per week for 8 weeks.

Drug: BaidI Quzhi granuleDrug: Ju Yin cream

TCM internal treatment group

ACTIVE COMPARATOR

Participants in the TCM internal treatment group will receive Baidi Quzhi granule two times daily after meals and Ju Yin placebo therapy three times per week for 8 weeks.

Drug: BaidI Quzhi granuleDrug: Ju Yin placebo cream

TCM external treatment group

ACTIVE COMPARATOR

Participants in the TCM external treatment group will receive Baidi Quzhi placebo granule two times daily after meals and Ju Yin cream therapy three times per week for 8 weeks.

Drug: Ju Yin creamDrug: Baidi Quzhi placebo granule

Placebo group

PLACEBO COMPARATOR

Participants in the placebo group will receive Baidi Quzhi placebo granule two times daily after meals, Ju Yin placebo therapy three times per week for 8 weeks.

Drug: Baidi Quzhi placebo granuleDrug: Ju Yin placebo cream

Interventions

Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

Also known as: Chinese Herbal Medicine
TCM comprehensive treatment groupTCM internal treatment group

Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

Also known as: Chinese Herbal Medicine
TCM comprehensive treatment groupTCM external treatment group

Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

Also known as: Chinese Herbal Medicine
Placebo groupTCM external treatment group

Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

Also known as: Chinese Herbal Medicine
Placebo groupTCM internal treatment group

Eligibility Criteria

Age16 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • \- 1. Patients with acne vulgaris aged from 16 to 45, male or female. 2. Patients who meet the western diagnostic criteria of mild and moderate acne vulgaris and the differentiation criteria of TCM syndrome (15,16).
  • \. Patients who voluntarily join this study with informed consent. 4. No acne drugs were received within 1 month, and no external drugs related to the disease were used within 1 week.

You may not qualify if:

  • \. Patients with severe primary diseases such as cerebrovascular, cardiovascular, liver, kidney and hematopoietic system.
  • \. Participants will be ineligible if they ate pregnant or lactating women, and those with fertility plans in the next 2 years.
  • \. Allergic constitution and allergic to the drug ingredients studied in this project.
  • \. Cicatricial constitution. 6.Occupational acne caused by chemicals, acne caused by drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Study Officials

  • Jia Zhou

    Shanghai Yueyang Intergrated Medicnie Hospital,Shanghai

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2020

First Posted

September 5, 2021

Study Start

December 1, 2021

Primary Completion

July 1, 2023

Study Completion

August 31, 2023

Last Updated

September 5, 2021

Record last verified: 2021-08